Ultrasound Question for the Week of November 21, 2016



I work in a hospital. We are going to begin offering liver ultrasound with contrast. My understanding is that LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension contrast material is injected through an intravenous line. Do we report code 76705 for this? Can we bill the contrast material?



For services to non-Medicare patients you would report 76705 for the ultrasound and Q9950 for LUMASON®, the contrast agent, and 96374 for the administration of the contrast material. Note that code Q9950 for LUMASON® is billed per mL, each vial contains 5mL. Report used and discarded product for a total of 5mL.

For Services to Medicare patients prior to October 1, 2016 the coding would be the same. After October 1, 2016, you would not report 76705 but would report HCPCS code C9744 along with the contrast agent Q9950. HCPCS code C9744 may be accepted for non-Medicare patients, verify instructions from your commercial payers.

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension

LUMASON is an ultrasound contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

LUMASON is contraindicated in patients with:
• Known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts
• History of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON



Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].

Please see full Prescribing Information including boxed WARNING at http://imaging.bracco.com/us-en/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by BRACCO Suisse S.A., Plan-les-Ouates Geneve, Switzerland (Lumason lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride, 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc.